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Signiﬁcant advances have occurred in our understanding of the pathogenesis of knee osteoarthritis (OA)
and some recent trials have demonstrated the potential for modiﬁcation of the disease course. The
purpose of this expert opinion, consensus driven exercise is to provide detail on how one might use and
apply knee imaging in knee OA trials. It includes information on acquisition methods/techniques
(including guidance on positioning for radiography, sequence/protocol recommendations/hardware for
magnetic resonance imaging (MRI)); commonly encountered problems (including positioning, hardware
and coil failures, sequences artifacts); quality assurance (QA)/control procedures; measurement
methods; measurement performance (reliability, responsiveness, validity); recommendations for trials;
and research recommendations.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: D.J. Hunter, Rheumatology
stitute, University of Sydney,
-2-9463-1077.
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Signiﬁcant advances have occurred in our understanding of the
pathogenesis of knee osteoarthritis (OA) and some recent trials
have demonstrated the potential for modiﬁcation of the diseasetd. All rights reserved.
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require that alongside the assessment of structural effects symp-
tom improvement be demonstrated3,4. The previous guidelines for
clinical trials published in 19965 included recommendations for
imaging with a predominant focus on radiography (commensurate
with the era) with some detail in the appendices on methods of
acquiring radiographs and use of magnetic resonance imaging
(MRI). There was little if any detail on the different imaging
methods available, the pitfalls inherent nor performance metrics of
different imaging markers.
The purpose of this data-based expert opinion, consensus driven
exercise is to provide detail to anyone involved in clinical OA trials,
imaging scientists and their respective teams on howonemight use
and apply this knowledge in disease modifying clinical trials uti-
lising knee imaging assessments. It includes information on
acquisition methods/techniques (including guidance on posi-
tioning for radiography, sequence/protocol recommendations/
hardware for MRI); commonly encountered problems (including
positioning, hardware and coil failures, sequences artifacts); quality
assurance (QA)/control procedures; measurement methods; mea-
surement performance (reliability, responsiveness, validity); rec-
ommendations for trials; and research recommendations.
Methods
This paper is the work of a large multidisciplinary group who
were invited to participate in the Osteoarthritis Research Society
(OARSI) Clinical Trials Imaging Working Group. This review began
with a search of Pubmed using terms of OA, knee, and imaging. We
also conducted general searches for manuscripts covering general
imaging and randomized control trial (RCT)methods, covering each
of the sub-topics below; from this literature we identiﬁed designs
and methods, as well as other manuscripts of high relevance. It
should be noted that the vast majority of this manuscript is based
upon expert opinion of the diverse multidisciplinary group
involved in this exercise. Authors of this review included multiple
experts familiar with different approaches for imaging of the knee
joint, including radiologists, rheumatologists, and engineers. This
expert opinion was generated via a series of teleconference and
email exchanges followed by generation of a series of recommen-
dations. This correspondence allowed the working group to iden-
tify additional topics and manuscripts for inclusion and to develop
and reach concurrence on a set of recommended principles for
inclusion of knee imaging methods in OA trials. Given the potential
for divergent perspectives for the trial recommendations and
research recommendations a survey was conducted of these
members to determine the strength of recommendation for each
point raised. Final recommendations were obtained by averaging
the responses to a survey among the 14 authors for the strength of
recommendation from 0 to 100. At the commencement of this
exercise all members of the working group were asked about
conﬂicts of interest and the results from those who were conﬂicted
were not included in the survey results. The focus of the content is
on radiography and MRI as the preferred imaging techniques with
some content on ultrasound when appropriate.
Image acquisition
Imaging of the knee can be obtained by a variety of modalities.
X-ray, ultrasound, computed tomography (CT) and MRI are most
widely used and well developed at this time. New trials are using
PET and SPECT/scintigraphy to evaluate knee OA6. There continue
to be limitations in the application of arthroscopy, ultrasound and
bone densitometry techniques in clinical OA trials; hence, their
acquisition methods are not discussed below.X-ray of the tibiofemoral joints
Radiography of the tibiofemoral joints is most often evaluated
with anteroposterior (AP) positioning7. Although supine (non-
weight bearing) AP images are easily and frequently obtained, the
joint space width (JSW) cannot be adequately estimated in that
position8. The AP standing view is the most frequently used view
in clinical practice, but not in clinical trials. Both knees can be
included using a 36  43 cm (14  17 in) detector system if the
thighs are not heavy or signiﬁcant varus is not present. Otherwise,
a single knee can be imaged with a suitable (e.g., 24  30 cm)
detector system. For the standing X-ray, care must be taken that
the knees be fully extended and against the cassette to avoid
distortion. The X-ray beam should be 6 caudad and a 180 cm (72
in) focus to ﬁlm distance, utilizing 65e72 kVP and a small focal
spot. With feet pointed straight ahead, the X-ray beam should be
centered midway between the knees (bilateral) or horizontally at
mid-patella (single knee) and about 1 cm below the apex of the
patella.
In cross sectional epidemiologic or symptom modifying clinical
trials, the posteroanterior (PA) X-ray is useful for supporting a
diagnosis of knee OA. For longitudinal epidemiologic or structure
(disease) modifying trials, the standing AP radiograph of the knee
does not adequately deﬁne joint space narrowing (JSN), as the
most severe changes in condylar articular cartilage are often
somewhat posterior9. To more accurately determine the narrowest
point in the medial compartment, BucklandeWright developed a
method of ﬂuoroscopically positioning the knee10. This and several
other techniques have been developed in order to have repro-
ducible positioning for semi-quantitative OARSI grading of JSN and
quantitative measurements of the medial joint space11,12. The basic
principle of these methods are to ﬁx the alignment of the medial
tibial plateau, while ﬂexing the knee at a reproducible angle in
order to capture the narrowest region of cartilage of the medial
condyle. The most commonly used techniques used at this time
are the ﬁxed-ﬂexion PA view and the ﬂuoroscopically aligned
Lyon-Schuss PA view, with the use of a SynaFlexer positioning
frame (BioClinica (formerly Synarc), San Francisco, CA)13e15. In the
Lyon Schuss view, the patellae and thighs are in contact with the
ﬁlm cassette and coplanar with the tips of the great toes. In the
(MTP) ﬁxed ﬂexion view the patellae are in contact with the
cassette and aligned vertically with the ﬁrst MTP joints with the
feet externally rotated 5. This results in reproducible ﬂexion of
the knee at approximately 20. The X-ray beam is angulated 10
caudad and centered on a reproducibly identiﬁable point in the
popliteal fossa of a single knee or midway between the two knees
at the level of the popliteal fossa if both knees are imaged
simultaneously, with the aim of aligning the beam tangential with
the ﬂoor of the medial tibial plateau. The Lyon Schuss technique
uses the same positioning and beam centering, but ﬂuoroscopi-
cally aligns the anterior and posterior rims of the medial tibial
plateau. Magniﬁcation correction is assisted by a projection
phantom on the SynaFlexer frame or by placing a ball bearing of
known dimension in the same position medial to the knee if im-
aging without the SynaFlexer. Fluoroscopic guidance, if done
correctly, provides high quality and optimally aligned images.
However, this requires more training and is not available at most
sites in a multicenter trial. A modiﬁed Lyon-Schuss (mLS) tech-
nique has been used successfully, requiring imaging the knee three
times with a 2 difference in tube head angle to ensure optimum
positioning as observed with the inter-margin distance16,17. It
should be noted that special images (long limb ﬁlms) were his-
torically recommended to adequately judge varus or valgus de-
formities, but more recently, the knee ﬁlm alone has been found to
be sufﬁcient18.
Table I
Semi-quantitative scoring MRI acquisition techniques30,31,38
Tissue Location Feature MRI technique Imaging plane
Primary Secondary Primary Secondary
Cartilage Tibiofemoral Focal defect PD FSE/T2 TSE with FS 3D T1-GRE with FS or WE Coronal Sagittal
Patella Focal defect PD FSE/T2 TSE with FS 3D T1-GRE with FS or WE Axial Sagittal
Trochlea or posterior femur Focal defect PD FSE/T2 TSE with FS 3D T1-GRE with FS or WE Sagittal
Bone marrow Tibiofemoral Lesions/cyst STIR/PD FSE 3D TSE/T1 w IV cont
TSE with FS or WE
Coronal Sagittal
Fracture T2 FSE/TSE with FS or WE or STIR T1 FSE/TSE Coronal Sagittal
Patella Lesions STIR/PD FSE 3D TSE/T1 w IV cont
TSE with FS or WE
Axial Sagittal
Fracture T1 without FS or STIR T2 FSE/TSE with FS or WE Axial Sagittal
Bone Tibiofemoral Osteophytes T1 FSE/TSE; GRE/SPGR, FLASH, DESS PD FSE/TSE with or without FS Coronal Axial
Patella Osteophytes T1 FSE/TSE PD FSE/TSE with or without FS Axial Sagittal
Trochlea Osteophytes T1 FSE/TSE PD FSE/TSE with or without FS Sagittal Axial
Meniscus Morphology/Tear PD, T1 FSE/TSE T2 FSE/TSE with FS; 3D FSE Sagittal Coronal
Extrusion PD, T1 FSE/TSE with FS T2 FSE/TSE with FS; 3D FSE Coronal Sagittal
Ligament/tendon ACL/PCL Tear T2 FSE/TSE with or without FS T1 FSE/TSE Sagittal Axial
Collateral Tear T2 FSE/TSE with or without FS T1 FSE/TSE Coronal Axial
Knee extensor Tear T2 FSE/TSE with or without FS T1 FSE/TSE Sagittal Axial
Synovium Peri-patellar fat pads Synovitis T1w þ IV with FS T2 PD FSE/TSE with FS or WE Sagittal Axial
Posterior cruciate recess Synovitis T1w þ IV with FS T2 PD FSE/TSE with FS or WE Sagittal Axial
Para-meniscal recess Synovitis T1w þ IV with FS T2 PD FSE/TSE with FS or WE Coronal Axial
Medial and lateral recesses
and suprapatellar bursa
Synovitis T1w þ IV with FS T2 PD FSE/TSE with FS or WE Axial Sagittal
Joint effusion Anterior compartment Fluid volume T1w FS CE, T2 FSE/TSE with or without FS PD FSE/TSE with or without FS Axial Sagittal
Popliteal cyst Fluid volume T1w FS CE, T2 FSE/TSE with or without FS PD FSE/TSE with or without FS Axial Sagittal
Muscle Myositis T2 FSE/TSE with FS or WE STIR Axial Sagittal
Atrophy T1 FSE/TSE Axial Sagittal
Bursae Pes anserine. MCL bursa Inﬂammation T1w FS CE, T2 FSE/TSE with FS or WE STIR Coronal Axial
Peri-patellar bursae Inﬂammation T1w FS CE, T2 FSE/TSE with FS or WE STIR Sagittal Axial
Deﬁnitions
PD FSE/TSE: Proton density weighted fast or turbo spin echo (TR > 2000 ms, TE in the range of 25 mse35 ms).
T2 FSE/TSE: T2-weighted fast or turbo spin echo (TR > 2000 ms, TE in the range of 40e60 ms).
T1 FSE/TSE: T1-weighted fast or turbo spin echo (TR < 1000 ms, TE in the range of 10e20 ms).
3D GRE: 3D gradient echo sequence 3D GRE 3D gradient echo sequence.
Short tau inversion recovery recommended in post-operative setting where there may be artifact due implanted.
STIR: metal.
FS: fat suppression.
WE: Selective water excitation used at 3 T.
T1w þ IV: T1 with intravenous contrast Gadolinium.
DCE: Dynamic gadolinium contrast enhanced perfusion imaging.
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A lateral view of the patellofemoral (PF) joint can be used to
supplement the ﬁndings on the AP view. In addition, measure-
ment of the lateral view radiographic tibiofemoral JSW may also
be of value19. The lateral PF view is often obtained with the patient
lying supine on the table, hips and knees ﬂexed with the heels on
the table enough to ﬂex the knees to 45. Additionally, determi-
nation of PF alignment and speciﬁcs of PF JSW (adequate deter-
mination of medial vs lateral PF involvement) are often viewed
with an axial (skyline, sunrise, sunset) image of the knee, obtained
with the X-ray beam parallel to the table and perpendicular to a
14  30 cm cassette. The X-ray tube is positioned 10e12 cm aboveTable II
Quantitative cartilage morphometry MRI acquisition techniques
Location MRI technique
Primary
Tibiofemoral 3D T1 GRE with FS or WE
Patella 3D T1 GRE with FS or WE
Trochlea or Posterior femur 3D T1 GRE with FS or WE
Resolution
Field strength Section thick
3 T 0.7 mme1.0
1.5 T 1.0 mme1.5the patella, anterior to the thigh with the ﬁlm cassette just distal
to the knee.MRI
Due to the limitations of radiography, MRI has been identiﬁed by
the OutcomeMeasures in Rheumatologic Clinical Trials (OMERACT)
and OARSI as the most appropriate imaging modality to assess joint
status in OA research studies20. MRI can detect structural pathology
associated with pain21,22 and other tissues involved in the disease
process such as cartilage damage, osteophytes, subchondral cysts,
joint effusions, ligament and tendon tears, Baker's cysts, synovitis,
meniscal tears, and subchondral bone marrow lesions23e31. MRI isImaging plane
Secondary Primary Secondary
3D DESS Sagittal Coronal
3D DESS Axial Sagittal
3D DESS Sagittal Axial
ness In-plane
mm 0.3 mme0.5 mm
mm 0.3 mme0.6 mm
Table III
Compositional cartilage imaging techniques142
Biomarker Underlying biological feature the biomarker
is believed to be a proxy for
Contributing tissues
T2 Collagen anisotropy and hydration Collagen and content, water diffusivity
T1rho Glycosaminoglycan content and meniscus Changes in water content predominantly meniscus
dGEMRIC Glycosaminoglycan content Water diffusivity
Contrast enhance CT Cartilage glycosaminoglycan Novel CT contrast agents rodent models of OA
Sodium MRI Cartilage glycosaminoglycan Suppresses signal from synovial ﬂuid
gagCEST Cartilage glycosaminoglycan Preliminary validation in the intervertebral disc and cartilage repair tissue
Diffusion Cartilage water mobility Calculates apparent diffusion coefﬁcient and T2
Ultra-short TE Osteochondral junction Isolate signal from the zone of calciﬁed cartilage
Deﬁnition
T2: spin spin relaxation time.
T1rho: Spin lattice relaxation in the rotating frame.
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ionizing radiation32.
The mechanisms of pain and mechanical dysfunction in OA are
not completely understood but are believed to involve multiple
interrelated pathways involving all joint structures23,26,33e37. MRI
protocols in OA research studies should be tailored for optimized
visualization of the tissue of interest and take into account the
image analysis method such as semi-quantitative scoring, quanti-
tative assessment of tissue dimensions (volume, thickness) or
biochemical composition20,30. For 3D volumetric cartilage analysis
dedicated high resolution sequences with good contrast between
cartilage and surrounding structures will be needed. “Whole-joint”
MRI protocols need to be tailored to evaluate all joint structures in
three imaging planes including ligaments, tendons, menisci, sub-
chondral bone, and synovium (see Table I)33,38.
MRI protocols for semi-quantitative evaluation of joint struc-
tures include two-dimensional fast or turbo spin-echo (FSE/TSE)
sequences, which have highly versatile tissue contrast that can be
used for comprehensive joint assessment. Two-dimensional FSE
images should be acquired in multiple planes to provide detailed
evaluation of all articular surfaces and all joint structures. Two-
dimensional ﬂuid sensitive sequences such as fat-suppressed in-
termediate-weighted or T2-weighted FSE or short tau inversion
recovery should be performed in at least one plane to allow
improved detection of ligament tears, bone marrow lesions, and
joint effusions. Protocols are optimally performed on a 3.0 T scan-
ner using multi-channel phased-array extremity coils to optimize
signal-to-noise ratio (SNR)33. However, current 1.5 T scanners
provide image quality sufﬁcient for reproducible analysis for most
protocols.
MRI protocols should include 3D sequences if quantitative,
volumetric evaluation of articular cartilage is to be performed (see
Table II). Fat suppression is typically added to these sequences to
reduce chemical shift artifact and to optimize the overall dynamic
contrast range of the image. 3D sequences are acquiredwith high in-
plane spatial resolution and thin continuous slices which reduce
partial volume averaging. Many 3D sequences have near-isotropic
resolution which allows articular cartilage and other joint struc-
tures to be evaluated in any orientation through the creation of high
quality multi-planar reformat images. Various three-dimensional
sequences have been used for quantitative cartilage assessment
within the knee joint including T1-weighted, fat-suppressed
gradient-echo39e41 and dual-echo in the steady-state (DESS)42.
Although the three-dimensional FSE/TSE techniques are
improving, there are still numerous drawbacks compared to the
more widely available 2D techniques: (1) image blurring when
using 3D FSE sequences secondary to T2 modulation of the point
spread function, (2) decreased contrast for evaluating soft tissue
structures including bone marrow lesions, ligaments, tendons, and
menisci (3) greater variation between manufacturers, (4) longerimage acquisition time which increases likelihood of motion, (5)
increased susceptibility tometallic artifacts. Although, 3D gradient-
echo sequences have been validated and applied for volumetric
cartilage assessment for over a decade43, there are few studies
available using 3D FSE/TSE sequences for semi-quantitative
assessment44.
Gradient-echo sequences were the ﬁrst 3D sequences used to
evaluate articular cartilage. Gradient-echo sequences can be
divided into dark ﬂuid sequences and bright ﬂuid sequences based
upon the signal intensity of synovial ﬂuid. Dark ﬂuid sequences
include T1-weighted spoiled gradient recalled-echo (SPGR, GE
Healthcare), fast low angle shot (FLASH, Siemens Medical Systems),
or steady-state free precession (SSFP, GE or 3D-FISP, Siemens) and
T1-fast ﬁeld echo (T1-FFE, Philips Healthcare). Bright ﬂuid se-
quences include T2*-weighted gradient recalled-echo acquired in
the steady-state (GRASS, GE Healthcare), gradient recalled-echo
(GRE, Siemens Medical Systems), and fast ﬁeld-echo (FFE, Philips
Healthcare). These sequences have been combined with a variety of
fat-suppression techniques including frequency selective fat-satu-
ration41,45,46, water excitation47,48, and iterative decomposition of
water and fat with echo asymmetry and least squares estimates
(IDEAL)49e51. Bright ﬂuid gradient-echo sequences have been found
to be the most useful for detecting cartilage lesions in clinical
practice and OA to perform cartilage thickness measurements in OA
research39e41,45,46,52. The main disadvantage of using dark ﬂuid
sequences for clinical cartilage imaging is that the low signal in-
tensity of synovial ﬂuid may decrease the conspicuity of superﬁcial
cartilage lesions51,53.
Driven equilibrium fourier transform (DEFT) and DESS are
additional three-dimensional sequence used to evaluate articular
cartilage. DEFT uses a 90 pulse to return transverse magnetization
to the z-axis which increases the signal intensity of tissues such as
synovial ﬂuid with long T1 relaxation times. Cartilage signal is
relatively preserved on DEFT images due the use of short echo
times48,54,55. DESS acquires two gradient echoes separated by a
refocusing pulse which are combined into a single image. Adding
the two echoes enhances the T2*-weighting of the image and in-
creases the signal intensity of both cartilage and synovial ﬂuid56.
DEFT and DESS utilize frequency selective fat-saturation54,55 or
water excitation57,58 to suppress signal from adipose tissue. Both
sequences produce multi-planar images of the knee joint with
bright synovial ﬂuid which creates an arthrogram-like effect that
increases the conspicuity of superﬁcial cartilage lesions. A water
excitation DESS sequence with 0.4 mm  0.5 mm in-plane spatial
resolution and 0.7 mm slice thickness is currently being used in the
Osteoarthritis Initiative to provide detailed cartilage assessment42.
Three-dimensional FSE sequences such as fast spin-echo Cube
(FSE-Cube, GE Healthcare) and sampling perfection with applica-
tion optimized contrasts using different ﬂip angle evolutions
(SPACE, Siemens Medical Systems) have also been used to evaluate
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constrain T2 decay over an extended echo train which allows
intermediate-weighted images of the knee joint with isotropic
resolution to be acquired with minimal blurring. Three-
dimensional FSE sequences typically use frequency selective fat-
saturation to suppress signal from adipose tissue59,60. FSE-Cube
and SPACE have lower in-plane spatial resolution and greater im-
age blurring when compared to other three-dimensional cartilage
imaging sequences with similar acquisition times which may
decrease the conspicuity of superﬁcial cartilage lesions61,62. How-
ever, these sequences have highly versatile intermediate-weighted
contrast which can be used to evaluate all joint structures. In fact,
three-dimensional FSE sequences with multi-planar reformats has
been shown to provide near identical “whole-organ” knee joint
assessment in OA research studies as axial, sagittal, and coronal
two-dimensional FSE sequences in shorter periods of time by
eliminating the need to acquire images with identical tissue
contrast in multiple planes44. It should be noted, however, that the
image quality of the reformations is not comparable with the ac-
quired source images and that reformations cannot fully substitute
2D images obtained in the same orientation63.
For cartilage quality studies quantitative mapping techniques
have been used to measure MRI parameters that are sensitive to
early changes in the composition and structural organization of the
extra-cellular cartilage matrix that precede loss of tissue detected
with standardMRI techniques (Table III). Techniques that have been
applied in clinical trials include cartilage T2 mapping (which has
been included in the OAI protocol), T1rho mapping, and delayed
gadolinium enhanced MRI of cartilage (dGEMRIC) and have been
the focus of several review articles64e66. dGEMRIC can provide
sensitive and speciﬁc information regarding the proteoglycan
content of cartilage67e70, but the technique requires a long waiting
period between contrast administration and image acquisition and
carries the risk of nephrogenic systemic sclerosis71,72. T2 and T1-
rho mapping have been shown to be sensitive for detecting early
cartilage degeneration in human subjects without the inconve-
nience and risks associated with the use of exogenous contrast
agents73,74. However, both techniques are not chemically speciﬁc,
but are inﬂuenced by concurrent changes in water content,
macromolecule content, and anisotropic organization that occur
during early cartilage degeneration. As such it is important when
interpreting the results of these techniques to realize that the
measured response to tissue degeneration is nonlinear and that
biochemical speciﬁcity of the response will generally decrease with
more advanced degeneration.
CT arthrography
CT arthrography can also be used to provide knee joint assess-
ment in OA research studies. CT is a widely available and relativelyFig. 1. (a). Positioning of the conventional extended knee AP or PA radiograph with horizont
the displacement of anterior and posterior margins (arrows) and difﬁculty identifying theinexpensive imaging modality which can rapidly acquire high
resolution volumetric source data that can be used to create
reformatted images in multiple planes. CT imaging has high
sensitivity for detecting various features of joint degeneration
including meniscus and ligament tears, cartilage loss (these ﬁrst
three features following the injection of iodinated contrast into the
knee joint), subchondral cysts and sclerosis, and osteophyte for-
mation75e78. The technique can also be used to measure the
thickness79,80 and proteoglycan concentration81,82 of cartilage.
However, CT arthrography is an invasive technique requiring radi-
ation exposure and intra-articular contrast administration which
has limited its use in longitudinal OA research studies. Also eval-
uation of bone marrow and ligaments is limited with CT compared
to MRI. A more recent study suggested CT may also have promise
for evaluation of calcium crystal deposition in the knee83.
Commonly encountered problems: positioning, hardware and
coil failures, sequences artifacts
Commonly-encountered problems in radiography
Projection
Radiography is a projectional technique in which 3D anatomy is
projected onto a 2D receptor, and therefore subject to morpholog-
ical distortion, magniﬁcation and superimposition of overlaying
structures. A reproducible radiographic image of the tibiofemoral
joint space thus requires adherence to exacting standards of
centering and angulation of the X-ray beam, and positioning of the
knee, which include speciﬁcations for ﬂexion and rotation of the
joint11. In amajority of patients, the anatomy of the knee is such that
full extension of the joint (as is required for a conventional weight-
bearing extended-knee radiograph) tilts the tibial plateau to an
angle that is skew (i.e., not parallel) to a horizontally directed X-ray
beam84 [Fig. 1(a)]. Skewed radio-anatomic alignment of the tibial
plateau in an AP or PA knee radiograph is apparent in the excessive
displacement of the anterior and posterior margins of the medial
plateau [Fig. 1(b)]. When the alignment of the plateau is notably
skewed, the ﬂoor of the joint space can become indistinct, and a key
reference point for the measurement of minimum JSW (minJSW) is
less reliably ascertained. Typically it is recommended that the inter-
marginal distance (IMD) should be 1.5 mm85 or even 1 mm86.
Although, other studies suggest that while stability of the IMD be-
tween visits matters, as a metric of reproducible projection, small
differences in absolute IMD may not empirically affect JSN87.
1 Flexion of the knee, rotation of the knee
If the articulating surfaces of tibia and femur overlap or the
anterior and posterior tibial rims are grossly malaligned, unclear
visualization or artiﬁcial variation of the JSW may result [Fig. 1(b)].al beam. (b). Skewed radio-anatomic alignment of the medial tibial plateau apparent in
cortex of the ﬂoor of the plateau.
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problems in longitudinal studies88, Fig. 2).
Further, articular cartilage loss in the knee most commonly
begins along a region of the femoral condyle that is posterior to that
which articulates with the tibial surface when the knee is in full
extension. Since radiographic joint-space width reﬂects cartilage
thickness only where the femoral and tibial articular surfaces are in
direct contact, positioning the knee in full extension can be
insensitive to early cartilage loss. Mild ﬂexion is thus needed to
articulate this active portion of the femur with the central tibia and
detect early cartilage loss. Moreover, since cartilage loss progresses
heterogeneously in the knee, knee ﬂexion as well as beam
centering and angulation must be exactly the same on serially ac-
quired radiographs for longitudinal assessments of JSN to be valid.
Different degrees of rotation of the knee may cause different
degrees of overlap between osteophytes and the margin of femur/
tibia, leading to non-visualization of previously seen osteophytes,
exposure of previously obscured osteophytes, or a discrepancy in
their apparent size between timepoints when in fact there has been
no real change in size.
2 Weight bearing
As noted above, radiographic joint-space width can be valid as a
measure of cartilage thickness only when the two opposing carti-
lage surfaces of interest are in direct contact with each other. The
knee must therefore be loaded in order to ensure this. However,
weight bearing during radiography poses a number of additional
challenges89. For example, longitudinal changes in weight bearing
(for example, due to weight gain or loss) may affect the extent of
voluntary knee extension. Accordingly, effort must be taken in se-
rial examinations to ﬁx the degree of ﬂexion reproducibly. Changes
in the distance between the knee and radiographic cassette may
alter the degree of radiographic magniﬁcation in the image. These
sources of error seriously limit the utility of the knee radiograph toFig. 2. Radiographs at baseline and 2-year follow-up of a 61-year-old woman with OA. At tw
AP radiograph taken at 5 angulation shows medial JSN (OARSI grade 2 and KLG 3). (b) H
Similarly, at follow-up, AP radiograph taken at 5 angulation shows OARSI grade 2 JSN (KLG
(b) and (c) are compared longitudinally, one observes a paradoxical ‘joint space widening’.detect true reduction in JSW, the cardinal indicator of progression
of knee OA. While these challenges are recognized, recent studies
have demonstrated that with careful site technologist training,
using a weight bearing acquisition technique, careful unilateral
imaging of each knee (not a bilateral knee radiography), proﬁcient
quality control (QC) of the radiography by a core lab experienced in
the technique, either the ﬁxed ﬂexion ormLS technique can provide
reproducible images to allow evaluation of a disease modifying
osteoarthritis drugs (DMOAD) in a large multi-center clinical trial.
3 X-ray beam angle
Variation in X-ray beam angle can result in apparent difference
in the JSW (Fig. 3). This can also cause artiﬁcial variation in JSW in
longitudinal studies.
Commonly-encountered problems in MRI
In clinical trials of knee OA, the images need to cover the whole
knee joint. For optimal images, the joint should be centered at the
midpoint of the coil and the iso-center aligned caudal to the distal
endof thepatella. Thatguarantees full coverageof theknee.However
if the synovialﬂuid is to bemeasured, theﬁeld of view (FOV)must be
shifted proximally to ensure that all parts of the joint capsule are
covered in both the proximal-distal and medial-lateral directions.
Imaging plane alignment
The curved shape of the femoral condyles and the patella re-
quires selection of an imaging plane perpendicular to the curvature
to provide clear views of the cartilage surface and to minimize
partial volume effects. Imaging planes should provide the best
views of articulating cartilage, bones and soft tissue structures both
for scoring and quantitative assessment of cartilage, bone marrow
lesions, and meniscus30,90. Selection of an oblique imaging plane
aligned with the anterior cruciate ligament may be helpful foro time points, radiographs were taken with 5 , 10 , and 15 angulation of the knee. (a)
owever, AP radiograph taken at 10 angulation shows OARSI grade 3 JSN (KLG 4). (c)
3) whereas that taken at 15 angulation (d) shows OARSI grade 3 JSN (KLG 4). If images
Fig. 3. In this example using ﬁxed ﬂexion PA protocol, the joint space will appear
wider when a beam that is parallel to the tibial plateau is used (thick dotted line)
compared to when a beam is slightly angulated with respect to the tibial plateau (thin
dotted line). Therefore, tube angulation needs to be kept constant between time
points, as well as the angle of ﬂexion of the knee. For the mLS technique with varying
angles at baseline, the technologist at acquisition has to reference the baseline
radiograph and tube angle used.
D.J. Hunter et al. / Osteoarthritis and Cartilage 23 (2015) 698e715704assessing ligament integrity30,90. However, for quantitative analysis
of the whole femoral cartilage including the trochlea and posterior
femoral condyles and patella, sagittal images are preferred. If
analysis is limited to cartilage of the weight bearing regions, cor-
onal images can be used.
In order to avoid oblique knee images, the feet should be posi-
tioned with the big toe up91. This eliminates knee rotation, and
standardizes knee positioning across study subjects and time-
points. Further, MRI sections should be oriented with careful
biplanar alignment based on reproducible anatomical landmarks.
Image resolution
Quantitative cartilage imaging is demanding for resolution, with
slice thickness from 0.7 to 1.5 mm and in plane resolution from
0.3  0.3 mm to 0.5  0.5 mm necessary to reliably detect and
follow small defects less than 5 mm2. This is driven by sampling
theory, which recommends that twice the sampling frequency of
the signal bandwidth is required for reliable detection of lesions;
this case means twice the geometric diagonal of the voxel size for
reliable feature detection. In knee OA the pattern of cartilage loss
varies from an increase in size of a single defect to thinning of the
cartilage over a large area, therefore a slice thickness of 1e1.5 mm
and in-plane resolution of 0.4  0.4 mm or greater are recom-
mended30,90. In this context it is important to note that quantitative
analysis of cartilage volume and thickness does not require
isotropic resolution; a pixel size of 0.3  0.5 mm is acceptable
allowing for faster anatomical coverage along the longer dimension.
Standardization of slice thickness across longitudinal timepoints
is important in scoring change in both cartilage and bone marrow
lesions as the grade is determined by the number of slices the
feature is observed in. Therefore all sites must comply with the
speciﬁed standardized imaging protocol. In addition, incoming data
QC needs to include veriﬁcation of imaging parameters, including
slice thickness and in-plane resolution92. To avoid future errors, and
maximize the chance of recalling subjects when necessary for re-
imaging and retaining them in the study, feedback to imaging
sites needs to happen quickly and on an ongoing basis.
Imaging sequences
The goals of imaging sequences for morphological cartilage
analysis are high in-plane resolutionwithhigh contrast tonoise ratiobetween cartilage and all adjacent tissues and ﬂuid. Many of the
techniques are manufacturer-dependent, but most include some
type of fat suppression or selective water excitation and 3D FSE or
gradient echo sequence, although 2D FSE is sometimes used for
semi-quantitative scoring. All of those sequences have been vali-
dated for imaging of cartilage62,93e97. Their ability to show the
boundaries between bone-cartilage, cartilageecartilage, cartilage-
degenerated meniscus, cartilage-inﬂamed synovium, and cartilage-
inﬂamed synovial ﬂuid varies. While selecting a sequence it is
important to take care that the imaging parameters are also chosen
in such away that the visualization of those interfaces are optimized,
particularly those with the greatest impact on study endpoints.
MRI is used for compositional assessment including tech-
niques such as T2 imaging, dGEMRIC and T1 rho imaging. This
imaging has similar resolution dependencies as quantitative
morphologic imaging. Thick slices and low in-plane resolution will
limit detection to generalized changes and prevent detection of
local abnormalities and their progression. For T2measurements the
ideal slice thickness is 2 mm, but for practical purposes 3 mm
resolution may be needed98,99. There are varying opinions of the
number of echoes needed in the multi-echo spin echo series for
repeatable T2 calculations, varying from two echoes to 11
echoes98,99. The practical issue is that the larger the number of
echoes the smaller the number of slices, subsequently limiting
coverage of the knee. Regardless of the number of slices, however,
assessments are only useful for comparison if the area covered and
the imaging plane used are the same from time point to time point.
Standardization (consistency of image acquisition parameters
within the study) of image acquisition cannot be overemphasized.
The variability of T2 measurements between different manu-
facturers and different imaging units is a well-known confounding
factor. The effect of the variability can be minimized by using small,
standardized T2 phantoms, which are positioned in the imaging
ﬁeld of view of the T2 series acquired for each subject at each time
point. This will enable pooling of T2 data across multiple sites and
equipment and verify possible change between time points100. At
this time, T1 rho sequences have not been validated for use in OA
trials, therefore their use is currently limited to experimental ter-
tiary endpoints.
Since both quantitative and qualitative assessments may use fat
suppressed/saturated sequences, heterogeneous fat suppression
due to ﬁeld heterogeneity will affect analysis results73,101. Since the
cartilage thickness changes over time are generally relatively small,
geometric distortion can affect the reliability of the results. The
stability of ﬁeld homogeneity should be monitored by scanning
special uniformity and linearity phantoms at the start of the study
and periodically throughout92. Transmit/receive as well as receive
only coils, which are used for knee imaging have a tendency to start
failing slowly102. Therefore, phantom scanning also should monitor
their performance throughout the study. Although a relatively rare
occurrence, changes in imaging performance can be caused by
software or hardware upgrades to the scanner, or problems
requiring a re-shim to correct. Periodic phantom scanning can
detect these issues before too much study data has been acquired.
In addition to the difﬁculties outlined above there can be difﬁ-
culties in safely putting patients with pacemakers or imbedded
metal foreign objects inside the magnet. A small proportion of pa-
tients have problems with claustrophobic reactions. The size of the
joint being imageddfor example a large knee in an obese patient-
dmay be too large for the cylindrical RF coil typically used, leading
to potential impaired image quality. Researchers need to be aware
of commonly encountered MR artifacts. Screening for artifacts that
potentially hinder adequate and appropriate image assessment
should be part of standardized QA procedures that are discussed in
detail in the next section. The challenges in conjunction with MRI
D.J. Hunter et al. / Osteoarthritis and Cartilage 23 (2015) 698e715 705artifacts have been reviewed extensively. A detailed discussion of
these would be beyond the scope of this manuscript103.
QA/control procedures
Clinical trials are becoming more complex, and from a regula-
tory perspective, they are underpinned by an over-arching quality
process or Good Clinical Practice (GCP)104. The understanding of the
GCP framework is critical to ensure the management of all aspects
of clinical trials, not least of which is the imaging. Essentially, this is
twofold: data integrity and subject protection105. From an imaging
perspective, more recently the requirements speciﬁcally for medi-
cal imaging in clinical trials, including the necessary documenta-
tion, such as an Imaging Charter have been detailed by the Food and
Drug Administration (FDA)92. Potentially more practical details for
the charter and review of read systems have been described in
detail recently106. A systematic approach is required to ensuring
quality as detailed below107:
 Personnel roles and responsibilities
 Training
 Policies and procedures
 QA and auditing
 Document management, record retention, and reporting
 Corrective and preventive action (CAPA)
There is a major difference between QC and QA:
Quality control, as stated by the ISO deﬁnition, is the summari-
zing term covering the operational techniques that are used to
fulﬁll requirements for quality. In the context of medical imaging in
clinical trials, this includes the framework of the documents
described and the checking of the medical imaging data by a third
party such as an imaging core lab. A diagrammatic representation is
shown in Fig. 4.
Quality Assurance comprises the overarching procedures that
are put in place to ensure quality, which includes the checking and
audit of the process and QC systems that have been instigated.
Medical imaging QC in clinical trials
When evaluating the QC procedures one needs to understand
the key aspects of the use ofmedical imaging inmedicine in general:
(1) Diagnosis; (2) Prognosis or screening; (3) Monitoring of therapy
and (4)Monitoring of natural history in order to initiate, refrain from
or change therapy. In clinical trials one usually considers efﬁcacy
measures, which are items 3 & 4 (monitoring therapy, and moni-
toring natural history for placebo controlled studies). For eligibility,
items 1 and 2 are relevant. There are different metrics that have to
be considered for each of these uses. KLG108 is used for eligibility but
it does not have the sensitivity or precision for efﬁcacy and hence
the radiographic QC may differ when applying radiographic KLG forFig. 4. QC, retrieved from http://www.transition-support.eligibility compared to reduction in radiographic JSW being used as
an outcome in longitudinal studies looking at efﬁcacy.
The challenge at screening in regard to required image quality is
to account for both, the requirements of eligibility and efﬁcacy: e.g.,
if JSW loss is the primary end point in a clinical trial, then the
acquisition of the knee X-ray has to be of sufﬁcient quality for the
JSW measurement, but for a pure screening KLG acquisition, a
standard AP ﬁlm may be adequate, as when an analgesic is being
developed without DMOAD properties.
Cross-calibration
Depending on the end-point, cross-calibration may be an
optional requirement. For many outcomes in clinical trials the key
end point is percentage change frombaseline. If each subject is used
as their own control (i.e., compare follow up with baseline or pre-
vious follow-up visits), then cross calibration is not required. This is
certainly the case with all radiographic and MRI endpoints in
DMOAD studies. However, it has to be ensured that image acquisi-
tion at serial visits is performed in identical fashion including tech-
nical aspects such asMRI or radiography system, sequence protocols
used,positioningandothers. This leads toa setofQC features thatare
required regardless of the anatomical area being evaluated:
1. Radiographs. If a grading scale is being used, then no calibration
is required, but the above mentioned items in regard to repro-
ducibility of image acquisition apply also for studies using
ordinal outcomes. If JSW or another quantitative end point is
being used, then a calibration marker or markers have to be
placed and be visible in the FOV at about the same distance to
the detector as the joint is located, to minimize the effects of
beam divergence and magniﬁcation.
2. MRI. If a scoring or grading system is being used, no calibration
is required (other than the routine standard ones conducted at
the site for correct instrument use). However, full anatomical
coverage and comparable sequence protocols are a requirement
for longitudinal comparison. If cartilage volume, thickness or
other quantitative parameters are being measured, very speciﬁc
calibration phantoms should be used, which are anatomic and
end-point speciﬁc. For continuous biomarkers such as these
quantitative measures then multivendor trials should demon-
strate and document that the biomarker values are comparable
across vendors and across centres. Subjects must always be
scanned on the same instrument on which they had their
baseline measurement, and using identical imaging parameters,
regardless of methodology being applied. If change in quanti-
tative cartilage is to be measured, then 3 T with phased-arrays is
recommended, while if whole-organ scoring is the primary aim,
then any 1.5 T or 3 T system which passes QA can be used.
3. Ultrasound. Ideally all the equipment should be standardized
across all sites. If not, then each subject must be scanned usingcom/Quality_control.htm accessed 05 February 2014.
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data has to be very conscientious in marking up the scans so the
technologist providing QC can follow the joint and positioning.
Instructions manual
For all imaging, instruction manuals or “cheat sheets” must be
provided to all sites detailing the speciﬁc acquisition requirements.
Without this set of details, QC cannot be conducted.
Reader “training” or calibration
For all the imaging evaluations performed in OA clinical trials,
radiologists or radiologist-trained readers may be involved in the
clinical study as readers. If only one reader is used, a regular cali-
bration process is needed during the course of a longitudinal study
to avoid shift/drift in readings. If more than one reader is to read the
images (highly recommended, except for small studies), then it is
important to bring the readers together for a calibration meeting
for the following speciﬁc reasons:
1. Training on the reading protocol
2. Trainingon the reading interface (unless theyhaveused the same
speciﬁc software and hardware conﬁguration in prior work).
3. To gain concordance in understanding the grading requirements
4. To undertake intra- and inter-reader agreement evaluation. It is
important that the reliability assessment is performed on an
adequate number of cases that takes into account the charac-
teristics of a speciﬁc cohort. It is important to assess reliability in
a cross-sectional as well as longitudinal fashion as detection of
change is the most important parameter in clinical trials.
Further an adequate number needs to be included in reliability
exercises. During the course of the study, inter-reader concor-
dance exercises should be conducted in an on-going manner. In
general the concepts provided here are outlines in the FDA draft
Guidance entitled “Guidance for Industry on Standards for
Clinical Trial Imaging Endpoints92”.
Knee X-ray speciﬁc QC
All knee acquisitions need to use a weight bearing ﬁxed ﬂexion
technique, such as ﬁxed ﬂexion or mLS using a positioning device,
such as the Synaﬂexer equipped with a calibration standard.
There are a number of factors that need to be considered when
evaluating QC for the knee for both eligibility and efﬁcacy:
1. Is there a single knee imaged per radiograph?
2. Are there calibration beads visible?
a. If not JSW cannot be measured
3. Is the knee in the center of the image?
4. Is there minimal rotation (as evaluated by the patellar position)
5. Is the cortex of the medial tibial plateau sharply delineated in its
entirety
a. Some studies suggest inter-margin distance should be 
1.5 mm
6. Does the inter-margin distance vary between visits?
7. Is anatomical coverage 10 cm above and below the tibial spines?
a. Is there correct alignment (deﬁned by anatomical angle axis)
and is it within protocol limits? (if needed for eligibility)Knee MRI speciﬁc QC
After checking the identiﬁcation of the participant, sequences
relative to the study protocol should be veriﬁed. Then, for eachacquisition, image quality should be validated according to the
following criteria:
- Integrity of all sequences (legible and complete sequences)
- Position of the knee in the FOV
- Contrast of tissues
- Motion artifact
- Other artifacts
- At follow-up visit, it is important to check that it is the same
knee as the knee that was imaged at baseline and that the im-
aging parameters are identical.
- QC results should be documented and archived in the partici-
pant's ﬁle.
- According to the study, the rejection of a QCmay necessitate the




Radiography can be used to visualize osteophytes, subchondral
cysts and sclerosis, alignment, and cortical irregularities. Radiog-
raphydoes notdirectly visualize articular cartilage,menisci, cruciate
or collateral ligaments, synovium, bursae, or the periarticular mus-
cles and ligaments, all of which can be better assessed by MRI.
Moreover, JSW is nonspeciﬁc, as it includes not only articular carti-
lage but meniscal tissue. Radiography is also limited by providing
only a 2D projection of the knee, which has a complex, 3D structure.
In clinical trials, the PA radiograph is useful for supporting a
diagnosis of kneeOA. Although theKLG system is over 60 years old, it
continues to be a useful method for eligibility screening for clinical
trials108,109. According to the KLG the presence of a deﬁnite osteo-
phyte is consistent with the diagnosis of OA (KLG 2). The presence of
deﬁnite JSNand osteophytes is consistentwithmoderate OA (KLG 3).
There are more detailed methods for deﬁning individual
radiographic features (including the OARSI atlas) that are useful in
more speciﬁcally deﬁning the study population and ascertaining
progression of JSN110e112. Other radiographic scoring methods are
available (including the Spector Atlas113 and Doherty's line drawing
atlas114), however, they are less widely used.
Quantitative radiographic measures
Traditionally the progression of knee OA has been assessed by
measuring changes in JSW (typically in millimeters), i.e., the dis-
tance between the medial femoral condyle and medial tibial
plateau on plain radiographs, as the medial compartment is the
most common site of involvement in knee OA. Among the various
radiographic features of OA, JSW is considered the surrogate for
articular cartilage thickness although it also reﬂects the integrity of
the meniscus. Methods of measurement of JSW can be either
manual using callipers or a simple graduated ruler and a micro-
metric eyepiece, or semi-automated using computer software115.
MRI semi-quantitative scores
Semi-quantitative assessment of the joints by expert in-
terpreters of MRI data has increased our understanding of the
natural history of this complex disease. These are usually in ordinal
scales although for some features they are dichotomous/binary
(e.g., ACL disruption). Several reliable and validated semi-
quantitative scoring systems now exist and have been applied to
large-scale, multicenter, cross-sectional and longitudinal observa-
tional epidemiological studies. Semi-quantitative MRI outcome
D.J. Hunter et al. / Osteoarthritis and Cartilage 23 (2015) 698e715 707measures have also been applied in several clinical trials in OA.
These include WORMS30, BLOKS116 and MOAKS31, which have been
extensively reviewed elsewhere recently38.
MRI e quantitative measurements
There is a wide variety of quantitative MRI measurement
methods including33 compositional measures such as (T1rho, T2
(sec) and T2* relaxation time measurements, GAG CEST, Sodium,
Diffusion and DTI, and dGEMRIC)64, as well as quantitative mea-
surements of cartilage (such as cartilage thickness, denuded area117
and morphological (CALS) score118) or other joint tissues for
quantitative morphological assessment (including 3D statistical
shape models and bone shape and dynamic contrast-enhanced and
non-contrast MRI synovitis). There are a range of methods used for
quantitative assessment of cartilage morphometry (volume (typi-
cally measured in mm3), thickness (typically measured in mm),
denuded area (typically measured in mm2)) ranging from fully
manual to fully automatic119e126. There is no clear data demon-
strating measurement performance superiority of one method over
another after direct comparison127. Similarly, quantiﬁcation of the
knee bone marrow lesions, osteophytes, meniscus, muscle volume,
bone area and shape128,129, synovitis and synovial ﬂuid are possible
and are demonstrating some important ﬁndings130,131.
Measurement performance (reliability, responsiveness,
validity)
Reliability of radiography in the knee joint
Reliabilityassessments forobserverbasedmeasures includeboth
inter and intra-observer measures as provided in ICCs or kappa
scores. There are different review articles available which provide
relatively consistent numbers132 with intra-reader variability of
about 0.95e0.97 (ICC) and only slightly lower inter-reader vari-
ability of about 0.93e0.95 (ICC) for JSW. However, these values are
highly inﬂuenced by the quality and grades of the radiographs being
evaluated, so should not be used as a gold standard, unless the same
set of images are being used to compare another set of radiologists.
The radiographic method did not affect the reliability132, however
the positioning of the knee joint plays a very important role.
Reliability of MRI in the knee joint
Concerning MRI the literature gets much more inconsistent and
the reliability is in part very much dependent on what one is
measuring and how one is doing this. To this end we would assert
that reliability is study speciﬁc and should be tested and reported
for each endeavour. The inter-reader and intra-reader ICCs are high
for quantitative as well as semi-quantitative morphological MRI
(range 0.80e0.94)133. However, the results are very much depen-
dent on the speciﬁc anatomical area within the knee joint which is
analysed with an increased range of ICCs e.g., for the quantitative
assessment of the synovium (range 0.61e1.00) or the semi-
quantitative assessment of the meniscus (range 0.49e1.00)133. For
quantitative cartilage morphometry the ICC ranges in various
studies for intra- and inter-rater reliability in between 0.86 and
0.95133. In compositional MR techniques, the range of the reliability
is higher and even more heterogeneous134. So far there is no sys-
tematic review on reliability issues in compositional MRI available.
Existing studies are reporting on ICC values for T2 mapping in be-
tween 0.61 and 0.9899,135. The reproducibility of T1-r values for
example was higher in the thicker patellar cartilage (ICC range,
0.86e0.93) than in the femoro-tibial joint with a large range of ICC
values in between 0.20 and 0.84.Responsiveness of radiography in the knee joint
The responsiveness of radiographic JSW can be assessed by
calculating the standardized response mean (SRM)132. The SRM is
one of several available effect size indices used to gauge the
responsiveness of scales to clinical change. The overall pooled SRM
was 0.33. Responsiveness of change in JSW measurement was
improved substantially in studies of greater than 2 years duration
(0.57). Further stratifying this result in studies of greater than
2 years duration, radiographs obtained with the knee in a ﬂexed
position yielded an SRM of 0.71132 although, like MRI this is likely
study speciﬁc.
Responsiveness of cartilage morphometry: thickness, area, volume
in the knee joint
The pooled SRM for quantitative measures of cartilage
morphometry for the medial tibiofemoral joint was reported
as 0.86133. For the quantitative analysis, SRMs are negative
because the quantitative value, indicating a loss of cartilage, goes
down. The pooled SRM for the semi-quantitative measurement of
cartilage morphology for the medial tibiofemoral joint was 0.55133.
For the semi-quantitative analysis, SRMs indicating a loss in carti-
lage are positive (increase in score).
Responsiveness of compositional measures: (T2, T1-rho, dGEMRIC,
Na) in the knee joint
The responsiveness as an instrument's ability to detect change
over time has so far not been assessed in the literature for
compositional MR techniques. Nevertheless for quantitative T2
mapping, recent reports from the incident and normal cohort of the
OAI support the use of cartilage T2 as an early marker of cartilage
degeneration, demonstrating responsiveness to cartilage change
over time136. Comparably also in other studies T2 mapping is seen
to provide stable and subtle longitudinal data137. A comparable
promising detection of longitudinal results can be found for
dGEMRIC138. For T1rho a number of studies also showed
responsiveness139.
For all other compositional sequences, the availability of
possible responsiveness to change is not yet available in literature.
Additionally the possibility of a real quantiﬁcation of most of the
compositional MR techniques enables them to reliably detect
changes of cartilage micro-structure.
Validity of radiography in the knee joint
The validity or accuracy is the degree to which an instrument
measures what it is supposed to measure is assessed here. In OA
progression can be assessed validly. For radiography, there is some
evidence for construct and predictive validity, with good evidence
for reliability of metric measurement of JSW140. It is important to
note that radiographic assessment concurrent and predictive val-
idity for clinical outcomes is weak and that JSW reﬂects a number of
structures not just hyaline articular cartilage3.
Validity of MRI in the knee joint
Concurrent validity of MRI in OA has been examined compared
to different parameters131. The relation of bone marrow lesions,
synovitis and effusion to pain was moderate to strong. There was a
weak or no relation of cartilage damage or meniscal tears to pain.
The relation of cartilage morphology to radiographic OA and
radiographic joint space was inconsistent. There was a higher fre-













































D.J. Hunter et al. / Osteoarthritis and Cartilage 23 (2015) 698e715708features in persons with radiographic OA. The relation of cartilage
to other constructs including histology and arthroscopy was
stronger. Predictive validity of MRI in OA has been examined for
ability to predict total knee replacement (TKR), change in symp-
toms, radiographic progression as well as MRI progression131.
Compositional MR techniques have been validated against histo-
logical samples with very promising results in exactly quantifying












































































































































































































































































































































































































































































































































































































































).Recommendations for trials (Table IV)
Trial recommendations are contingent on the goals of imaging
in clinical trials. For example imaging may play a role in: subject
selection; or monitoring progression/improvement; or deter-
mining the complications of disease or treatment.
Further to this the role of imaging in the clinical trial maybe for
internal decision making or for deﬁnitive proof of efﬁcacy. Internal
decision making studies may include proof of concept studies,
design considerations for phase III trials or phase IV (patient sub-
groups or different practice settings).
For image acquisition (whether radiography or MRI) we would
recommend.
i. Site training
ii. Image data-quality checks (completeness, correctness)
Regarding image analysis process we would recommend:
i. Central reading
ii. Multiple readers of the same images
iii. Individual patient imagesgrouped for processing for multi-
visit studies
iv. Adjudication
In reporting imaging studies in OA we strongly advocate
that authors describe in sufﬁcient detail the methods of
acquisition, image processing/analytic methods, QA and QC
steps in the methods section of the manuscript. This will
enhance both the readers ability to appraise the work and
others ability to replicate it. To facilitate clear and transparent


































































































































































































































































































































































































































































































































































































































The current hierarchy of claims for structural outcome as
deﬁned by the FDA Clinical Development Programs for Drugs, De-
vices and Biological Products Intended for the Treatment of OA
draft guidance is as follows:
1. Normalise the X-ray (reverse progression)
2. Improve the X-ray (halt progression)
3. Slow JSW loss by at least a pre-speciﬁed amount (slow the rate
of progression) accompanied by symptom improvement.
We support the continued use of JSWas one option for assessing
structural OA change, taking all the previous points into account

































































































































































spResearch recommendations (Table V)
Table V
Summary of research recommendations
Process Strength of recommendation
(range 0e100)*
Conventional radiography
With conventional radiography a special focus and further work should be on:
JSW: Measurement performance (reliability and responsiveness) dependency on projection technique, dependency on axial loading 72.2
JSW: Measurement performance (reliability and responsiveness) in the lateral femorotibial compartment 60.3
Bony changes (osteophytes, erosions, cysts, attrition): dependency of reproducibility on projection technique 51.8
Further investigation of the correlation of MRI cartilage thickness change, MRI meniscus change (position and size), and radiographic JSW change in different
stages of radiographic disease (i.e., healthy, pre-radiographic, early radiographic, advanced radiographic should be analysed). This knowledge is required to
achieve a paradigm shift from radiographic JSW to MR measurements.
74.1
What is their reliability (test-retest precision) and sensitivity to change across different (radiographic) stages of knee OA (i.e., from healthy, to pre-radiographic,
early radiographic, advanced radiographic).
71.3
What is their ability to predict the onset of pain in non-symptomatic subjects with and without radiographic change. 62.7
What is their ability to predict the onset of functional limitations in non-symptomatic subjects with and without radiographic change. 72
What is their ability to predict the onset of radiographic or other structural changes in subjects without deﬁnite radiographic change (KLG 0 or 1, with and
without symptoms).
70.2
What is their ability to predict a worsening in pain (progression) in subjects with mild to moderate pain levels (with and without radiographic change). 69.5
What is their ability to predict an increase in functional limitations (progression) in subjects with mild to moderate limitations (with and without
radiographic change).
69.8




Although there exists a comparison between quantitative cartilage volume/thickness with semi-quantitative scoring further comparison with scoring systems
such as eWORMS, BLOKS, KOSS and MOAKS should be performed.
55.4
Further investigation should also be done for compositional MR methods such as T2 mapping and gagCEST to ﬁnd correlations between macro-and microstructure
changes in the knee joint.
69.6
A correlation with clinical scores, clinical importance of individual variables in the semi-quantitative scoring systems as well as with quantitative values of the
compositional MR techniques should be performed.
78.8
Develop and appraise methods that will allow qualitative (semi-quantitative) measures to be quantitatively assessed as well as semi-automated to fully automated:
cartilage; bone (osteophytes, erosions, cysts, attrition, fractures, BML); menisci (surface, morphology, thickness, volume).
77.8
Evaluation of age dependence of structural changes (cartilage thickness and others) due to mechanical stress in different age groups (20e30, 30e40, 40e50 etc) 63.5
Improved detection, quantiﬁcation and measurement performance of structural, compositional changes of hyaline and ﬁbrocartilage (GAG, ﬁbre orientation, water content)
with the use of: T2 relaxation time measurements, T2* relaxation time measurements, gagCEST, T1rho, DWI, Sodium imaging, dGEMRIC
73.8
Development of semi-quantitative and quantitative as well as fully automated evaluation of inﬂammatory changes of the synovium, with the use of synovitis score,
non-contrast-enhanced sequences, dynamic contrast-enhanced perfusion studies, development of reproducible, standardized quantiﬁcation of perfusion
81.8
Evaluation of “inﬂammatory” changes in the subchondral bone marrow with the use of: DWI, T2*, dynamic contrast-enhanced perfusion studies. 72.8
Evaluation of muscle cross sectional areas (thigh), inter-muscular adipose tissue, intramuscular adipose tissue, and other imaging measures of muscle quality (in context of
muscle strength measurements) which are thought to play a potential role in the onset and progression of knee OA, but in particular for intra-muscular adipose tissue and
muscle quality, it is currently unclear which imaging technique is most accurate and precise for its evaluation.
75.2
Clinical validation of MRI methods and techniques in general:
What is their ability to predict virtual knee replacement endpoints?
What is their ability to predict real knee replacement?
How sensitive are different imaging measures to drug treatment (with different modes of action: i.e., affecting cartilage resorption, cartilage anabolism, bone resorption, other)
once DMOADs with these modes of action become available?
91.2

















D.J. Hunter et al. / Osteoarthritis and Cartilage 23 (2015) 698e715710Summary and conclusion
The goals of imaging the knee in clinical trials can include
subject selection, monitoring disease progression and treatment
effect, and/or identifying complications of the disease or the
treatment. For acquisition we have provided guidance with
regards both plain radiographic and MRI protocols. MRI protocols
must be optimized around the scientiﬁc objectives and unique
practical constraints of the speciﬁc study in question, particularly
with respect to the study centers. This manuscript includes a
number of recommendations for clinical trials that we would
advise anyone planning on using imaging in knee OA trial to
follow.
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